Status:
COMPLETED
Enhancing the Safety of Warfarin in Nursing Homes
Lead Sponsor:
University of Massachusetts, Worcester
Collaborating Sponsors:
Agency for Healthcare Research and Quality (AHRQ)
Qualidigm
Conditions:
Adverse Drug Events (ADEs)
Eligibility:
All Genders
Phase:
NA
Brief Summary
Oral anticoagulant therapy with warfarin is essential for the prevention of strokes and other thromboembolic events related to various medical conditions; however, use of this therapy can be associate...
Detailed Description
A. SPECIFIC AIMS Long-term oral anticoagulant therapy with warfarin is essential for the prevention of strokes and other thromboembolic events related to various medical conditions that increase in pr...
Eligibility Criteria
Inclusion
- Connecticut nursing homes affiliated with Qualidigm
Exclusion
- Nursing homes not affiliated with Qualidigm
Key Trial Info
Start Date :
September 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2009
Estimated Enrollment :
26 Patients enrolled
Trial Details
Trial ID
NCT00682773
Start Date
September 1 2006
End Date
September 1 2009
Last Update
August 4 2011
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Qualidigm
Middletown, Connecticut, United States, 06457
2
Meyers Primary Care Institute
Worcester, Massachusetts, United States, 01605